Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9945852 | 0.82 | HTR2C (0.39) | HTR2CHTR2AHTR2BCYP19A1MAPT | |
| SCHEMBL15943750 | 0.80 | KDM1A (0.47) | HTR2CHTR2AHTR2BMAPT | |
| SCHEMBL9947173 | 0.79 | HTR2C (0.50) | HTR2CHTR2AHTR2BSLC9A1LMNA | |
| SCHEMBL9945859 | 0.78 | MAPT (0.39) | HTR2CLMNACYP19A1MAOBMAPT | |
| SCHEMBL9947171 | 0.76 | HTR2C (0.47) | HTR2CHTR2AHTR2BSLC9A1LMNA | |
| SCHEMBL9947168 | 0.74 | HTR2C (0.45) | HTR2CHTR2AHTR2BSLC9A1LMNA | |
| SCHEMBL23705886 | 0.74 | HTR2C (0.58) | HTR2CHTR2AHTR2BLMNADDB1 | |
| Hydrochloric Acid SCHEMBL8467719 | 0.73 | HTR2C (0.46) | HTR2CHTR2AHTR2BSLC9A1LMNA | |
| SCHEMBL11537775 | 0.71 | NPC1 (0.45) | HTR2CHTR2AHTR2BSLC9A1LMNA | |
| SCHEMBL15763556 | 0.71 | HTR2C (0.41) | HTR2CHTR2AHTR2BSLC9A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422229-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| EP-2164324-B1 | THERAPEUTIC COMPOUNDS | UNIV FLORIDA (US) | 2014-08-13 | — | — | EP | disclosed |
| US-20140155490-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20100305212-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | HTR2C 1/4885HTR2A 7/4885HTR2B 21/4885 |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | HTR2C 1/4885HTR2A 7/4885HTR2B 21/4885 |
| US-20140155490-A1 | THERAPEUTIC COMPOUNDS | HTR2C, HTR3B, HTR2A | HTR2C 1/4885HTR2A 3/4885HTR2B 10/4885 |
| US-20100305212-A1 | THERAPEUTIC COMPOUNDS | HTR2C, HTR3B, HTR2A | HTR2C 1/4885HTR2A 3/4885HTR2B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.